Compartilhar
Informação da revista
Vol. 89. Núm. 5.
Páginas 492-498 (Setembro - Outubro 2013)
Compartilhar
Compartilhar
Baixar PDF
Mais opções do artigo
Vol. 89. Núm. 5.
Páginas 492-498 (Setembro - Outubro 2013)
ARTIGO ORIGINAL
DOI: 10.1016/j.jpedp.2013.01.005
Open Access
Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children
Adiposidade corporal, mas não resistência insulínica, associa-se ao polimorfismo -675 4G/5G no gene PAI-1 em uma amostra de crianças mexicanas
Visitas
...
Ulises de la Cruz-Mossoa, José Francisco Muñoz-Valleb, Aralia Berenice Salgado-Bernabéa, Natividad Castro-Alarcónc, Lorenzo Salgado-Goytiac, José Sánchez-Coronad, Silvia Esperanza Flores-Martínezd, Isela Parra-Rojasc,
Autor para correspondência
iprojas@yahoo.com

Corresponding author.
a BSc, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México
b Doutor, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México
c Doutora, Unidad Académica de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Chilpancingo, Guerrero, México
d Doutor, División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México
Informação do artigo
Abstract
Objective

To assess whether the -675 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is associated with obesity and insulin resistance in Mexican children.

Methods

A cross-sectional study was performed in 174 children, 89 with normal-weight and 85 with obesity, aged from 6 to 13 years. All children were from state of Guerrero, and recruited from three primary schools in the city of Chilpancingo, Mexico. Insulin levels were determined by immunoenzymatic assay. The homeostasis model assessment was used to determine insulin resistance. The -675 4G/5G polymorphism in PAI-1 gene was analyzed by polymerase chain reaction-restriction fragment length polymorphism.

Results

The prevalence of insulin resistance in the obese group was higher (49.41%) than in the normal-weight group (16.85%). The 4G/5G PAI-1 polymorphism was found in Hardy Weinberg equilibrium. The 4G/5G genotype contributed to a significant increase in waist-hip ratio (b = 0.02, p = 0.006), waist circumference (b = 4.42, p = 0.009), and subscapular skinfold thickness (b = 1.79, p = 0.04); however, it was not related with insulin resistance.

Conclusion

The -675 4G/5G genotype of PAI-1 gene was associated with increase of body adiposity in Mexican children.

Keywords:
PAI-1 gene
Polymorphisms
Body adiposity
Insulin resistance
Resumo
Objetivo

Elaboramos este estudo para avaliar se o polimorfismo -675 4G/5G no gene inibidor 1 do ativador do plasminogênio se associa à obesidade e à resistência insulínica em crianças mexicanas.

Métodos

Foi realizado um estudo transversal em 174 crianças, 89 delas com peso nor- mal e 85 obesas, variando sua idade de 6 a 13 anos. Todas as crianças eram do estado de Guerrero e foram recrutadas de três escolas primárias na cidade de Chilpancingo, México. Os níveis de insulina foram determinados por prova imunoenzimática. Foi usado o modelo de avaliação da homeostase para determinar resistência insulínica. O poli- morfismo -675 4G/5G no gene PAI-1 foi analisado pelo método reação de polimerase em cadeia-polimorfismo no comprimento dos fragmentos de restrição.

Resultados

A prevalência de resistência insulínica no grupo obeso foi mais alta (49,41%) do que no grupo com peso normal (16,85%). O polimorfismo 4G/5G do PAI-1 foi encon- trado em equilíbrio de Hardy Weinberg. O genótipo 4G/5G contribuiu para um aumento significativo da relação cintura-quadril (b = 0,02, p = 0,006), da circunferência da cintura (b = 4,42, p = 0,009) e da espessura da prega subescapular (b = 1,79, p = 0,04), mas não se relacionou com a resistência insulínica.

Conclusão

O genótipo -675 4G/5G do gene PAI-1 se associou a aumento da adiposidade corporal em crianças mexicanas.

Palavras-chave:
Gene PAI-1
Polimorfismos
Adiposidade corporal
Resistência insulínica
O texto completo está disponível em PDF
References
[1]
D. Ozel Demiralp, H. Aktas, N. Akar.
The effect of plasminogen activator inhibitor-1-675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation.
Clin Appl Thromb Hemost., 14 (2008), pp. 438-446
[2]
Y. Aso.
Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis.
Front Biosci., 12 (2007), pp. 2957-2966
[3]
B.R. Binder, G. Christ, F. Gruber, N. Grubic, P. Hufnagl, M. Krebs, et al.
Plasminogen activator inhibitor 1: physiological and pathophysiological roles.
News Physiol Sci., 17 (2002), pp. 56-61
[4]
H. Ha, E.Y. Oh, H.B. Lee.
The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.
Nat Rev Nephrol., 5 (2009), pp. 203-211
[5]
Z. Ma, D. Paek, C.K. Oh.
Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation.
Clin Exp Allergy., 39 (2009), pp. 1136-1144
[6]
C. Lopes, C. Dina, E. Durand, P. Froguel.
PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic caucasian population.
Diabetologia., 46 (2003), pp. 1284-1290
[7]
E.K. Kruithof.
Regulation of plasminogen activator inhibitor type 1 gene expression by inflammatory mediators and statins.
Thromb Haemost., 100 (2008), pp. 969-975
[8]
P.E. Morange, N. Saut, M.C. Alessi, J.S. Yudkin, M. Margaglione, G. Di Minno, et al.
Association of plasminogen activator inhibitor (PAI)-1 (SERPINE1) SNPs with myocardial infarction, plasma PAI- 1, and metabolic parameters: the HIFMECH study.
Arterioscler Thromb Vasc Biol., 27 (2007), pp. 2250-2257
[9]
N.H. Naran, N. Chetty, N.J. Crowther.
The influence of metabolic syndrome components on plasma PAI-1 concentrations is modified by the PAI-1 4G/5G genotype and ethnicity.
Atherosclerosis., 196 (2008), pp. 155-163
[10]
L. Bouchard, M.C. Vohl, S. Lebel, F.S. Hould, P. Marceau, J. Bergeron, et al.
Contribution of genetic and metabolic syndrome to omental adipose tissue PAI-1 gene mRNA and plasma levels in obesity.
Obes Surg., 20 (2010), pp. 492-499
[11]
P. Eriksson, B. Kallin, F.M. van ‘t Hooft, P. Båvenholm, A. Hamsten.
Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction.
Proc Natl Acad Sci U S A., 92 (1995), pp. 1851-1855
[12]
L.J. McCormack, D.K. Nagi, M.H. Stickland, M.W. Mansfield, V. Mohamed-Ali, J.S. Yudkin, et al.
Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome.
Diabetologia., 39 (1996), pp. 1512-1518
[13]
E.E. Kershaw, J.S. Flier.
Adipose tissue as an endocrine organ.
J Clin Endocrinol Metab., 89 (2004), pp. 2548-2556
[14]
J. Hoffstedt, I.L. Andersson, L. Persson, B. Isaksson, P. Arner.
The common -675 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene is strongly associated with obesity.
Diabetologia., 45 (2002), pp. 584-587
[15]
I. Silva-Zolezzi, A. Hidalgo-Miranda, J. Estrada-Gil, J.C. Fernandez- Lopez, L. Uribe-Figueroa, A. Contreras, et al.
Analysis of genomic diversity in Mexican mestizo populations to develop genomic medicine in Mexico.
Proc Natl Acad Sci U S A., 106 (2009), pp. 8611-8616
[16]
S. Ruiz-Quezada, M. Vázquez-Del Mercado, I. Parra-Rojas, H. Rangel- Villalobos, C. Best-Aguilera, L.V. Sánchez-Orozco, et al.
Genotype and allele frequency of PAI-1 promoter polymorphism in healthy subjects from the west of Mexico.
Association with biochemical and hematological parameters. Ann Genet., 47 (2004), pp. 155-162
[17]
I. Nuño-Arana, L.A. Páez-Riberos, L. Sando-val-Ramírez, J.M. Muñoz- Valle, D. Pinto-Escalante, J.M. Ceballos-Quintal, et al.
High prevalence of 5G allele in Amerindian tribes and mestizos from Mexico at 4G/5G PAI-I gene promoter polymorphism.
Thromb Haemost., 93 (2005), pp. 1005-1007
[18]
S.J. Dawson, B. Wiman, A. Hamsten, F. Green, S. Humphries, A.M. Henney.
The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells.
J Biol Chem., 268 (1993), pp. 10739-10745
[19]
M. Henry, N. Chomiki, P.Y. Scarabin, M.C. Alessi, F. Peiretti, D. Arveiler, et al.
Five frequent polymorphisms of the PAI-1 gene: lack of association between genotypes PAI activity, and triglyceride levels in a healthy population.
Arterioscler Thromb Vasc Biol., 17 (1997), pp. 851-858
[20]
K. Yamamoto, H. Saito.
A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders.
Int J Hematol., 68 (1998), pp. 371-385
[21]
I. Juhan-Vague, M.C. Alessi, P.E. Morange.
Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity.
Ann Med., 32 (2000), pp. 78-84
[22]
J.P. Bastard, L. Piéroni, B. Hainque.
Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance.
Diabetes Metab Res Rev., 16 (2000), pp. 192-201
[23]
P.E. Morange, H.R. Lijnen, M.C. Alessi, F. Kopp, D. Collen, I. Juhan-Vague.
Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.
Arterioscler Thromb Vasc Biol., 20 (2000), pp. 1150-1154
[24]
K. Schäfer, K. Fujisawa, S. Konstantinides, D.J. Loskutoff.
Disruption of the plasminogen activator inhibitor 1 gene reduces the adiposity and improves the metabolic profile of genetically obese and diabetic ob/ob mice.
FASEB J., 15 (2001), pp. 1840-1842

Como citar este artigo: de la Cruz-Mosso U, Muñoz-Valle JF, Salgado-Bernabé AB, Castro-Alarcón N, Salgado-Goytia L, Sánchez-Corona J, et al. Body adiposity but not insulin resistance is associated with -675 4G/5G polymorphism in the PAI-1 gene in a sample of Mexican children. J Pediatr (Rio J). 2013;89:492-8.

Copyright © 2013. Brasileira de Pediatria
Idiomas
Jornal de Pediatria

Receba a nossa Newsletter

Opções de artigo
Ferramentas
en pt
Taxa de publicaçao Publication fee
Os artigos submetidos a partir de 1º de setembro de 2018, que forem aceitos para publicação no Jornal de Pediatria, estarão sujeitos a uma taxa para que tenham sua publicação garantida. O artigo aceito somente será publicado após a comprovação do pagamento da taxa de publicação. Ao submeterem o manuscrito a este jornal, os autores concordam com esses termos. A submissão dos manuscritos continua gratuita. Para mais informações, contate assessoria@jped.com.br. Articles submitted as of September 1, 2018, which are accepted for publication in the Jornal de Pediatria, will be subject to a fee to have their publication guaranteed. The accepted article will only be published after proof of the publication fee payment. By submitting the manuscript to this journal, the authors agree to these terms. Manuscript submission remains free of charge. For more information, contact assessoria@jped.com.br.
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.